Is there a place for incretin therapies in obesity and prediabetes?
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Incretin-based therapies exploit the insulinotropic actions of the gut hormones gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1) for the treatment of diabetes and include GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4), the enzyme that inactivates the incretin hormones in the body. Both drug classes improve metabolic control in type 2 diabetes (T2DM), with GLP-1 receptor agonists also lowering body weight. Pharmacotherapy using DPP-4 inhibitors has few side effects and is weight neutral. Animal studies support their use in prediabetes; however, human data are scarce. GLP-1 receptor agonist effects are also apparent in non-diabetic obese individuals. Therefore, incretin-based therapies, if safe, may be effective in preventing progression of prediabetes; and GLP-1 receptor agonists may have potential for use in the treatment of obesity.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Trends in Endocrinology and Metabolism |
Vol/bind | 24 |
Udgave nummer | 3 |
Sider (fra-til) | 145-152 |
Antal sider | 7 |
ISSN | 1043-2760 |
DOI | |
Status | Udgivet - 13 feb. 2013 |
ID: 45840221